Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

12.04.2019 | leitlinien für die praxis

Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2019)

verfasst von: Monika Lechleitner, Susanne Kaser, Friedrich Hoppichler, Michael Roden, Raimund Weitgasser, Bernhard Ludvik, Peter Fasching, Yvonne Winhofer-Stöckl, Alexandra Kautzky-Willer, Guntram Schernthaner, Rudolf Prager, Thomas C. Wascher, Martin Clodi

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Leitlinie nimmt Bezug auf die Diagnostik, einschließlich begleitender Autoimmunerkrankungen, bei Typ 1 Diabetes mellitus, die Insulintherapie und die glykämischen Zielwerte.
Vorheriger Artikel „Diabesity“ – Adipositas und Typ-2-Diabetes (Update 2019)
Nächster Artikel Diabetes mellitus im Kindes- und Jugendalter (Update 2019)
Literatur
1.
ADA. Classification and diagnosis of diabetes. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41:S13–S26.CrossRef
2.
Chiang JL, Kirkman MS, Laffel LMB, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–54.CrossRef
3.
Buzzetti R, Zampetti S, Maddaloni E. Adults-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674–86.CrossRef
4.
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449–62.CrossRef
5.
SEARCH for Diabetes in Youth Study Group, Dabelea D, Rewers A, Stafford JM, et al. Trends in the prevalence of ketoacidosis in diabetes diagnosis: the SEARCH for Diabetes in the Youth Study. Pediatr Electron Pages. 2014;133:e938–45.
6.
Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and its progression to diabetes. JAMA. 2013;309:2473–4.CrossRef
7.
Mbanya CN, Motala AA, Sobngwi W, Assah FK, Enaru ST. Diabetes in sub-Saharan Africa. Lancet. 2010;375:2254–66.CrossRef
8.
Laugensen E, Ostergaard JA, Leslie RD, Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adults: current knowledge and uncertainity. Diabetes Med. 2015;32:843–53.CrossRef
9.
Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13:674–86.CrossRef
10.
Zaharia OP, Bobrov P, STrassburger K, Bodis K, Karusheva Y, Scholz M, Markgraf DF, Burkart V, Schloot NC, Müssig K, Szendroedi J, Roden M, GDS Group. Metabolic characteristics of recently diagnosed adult-onset autoimmune diabetes mellitus. J Clin Endocrinol Metab. 2018;103:429–37.CrossRef
11.
Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1, and type 2 diabetes. Diabetes. 2008;57:1433–7.CrossRef
12.
Cheng A, Hanna A, Kader T, Richardson S. Insulin therapy in type 1 diabetes. 2008. S. 46–52. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.
13.
Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol. 2017;13:385–99.CrossRef
14.
Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Norgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parvin HH, Thorsteinsson B, Tarnow L. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2:553–61.CrossRef
15.
Agesen RM, Kristensen PL, Beck-Nielsen H, Norgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parving HH, Thorsteinsson B, Tranow L, Pedersen-Biergaard U. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: the HypoAna trial. Diabetes Metab. 2016;42:249–55.CrossRef
16.
Kristensen PL, Tarnow L, Bay C, Norgaard K, Jensen T, Parving HH, Perrild H, Beck-Nielsen H, Christiansen JS, Thorsteinsson B, Pedersen-Bjegaard U. Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with type 1 diabetes. Diabet Med. 2017;34:625–31.CrossRef
17.
18.
Basu A, Pieber TR, Hansen AK, SAch-Friedl S, Erichsen L, Basu R, Haahr H. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab. 2018;20:1615–22.CrossRef
19.
Russel-Jones D, Bode BW, DeBlock C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Osterskov AB, Graungaard T, Bergenstal RM. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40:943–50.CrossRef
20.
Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2trial. Diabetes Care. 2017;40:951–7.CrossRef
21.
Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogues. Drug Healthc Patient Saf. 2010;2:213–23.PubMedPubMedCentral
22.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.CrossRef
23.
Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal aspart. Diabetes Care. 2003;26:590–6.CrossRef
24.
Woo VC. A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus. Clin Ther. 2017;39:S12–S33.CrossRef
25.
Blair HA, Keating GM. Insulin Glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76:363–74.CrossRef
26.
Robinson JD, Neumiller JJ, Campbell RK. Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin deglutec? Drugs. 2012;72:2319–25.CrossRef
27.
Lamos EM, Younk LM, Davis STN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.PubMedPubMedCentral
28.
Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, et al. Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care. 2017;40:554–60.CrossRef
29.
Rodacki M, Carvalho RM, Zajdenverg L. The potential effect of ultra-long insulin degludec on glycaemic variability. Diabetes Res Clin Pract. 2017;133:92–103.CrossRef
30.
But A, De Bruin ML, Bazelier MT, et al. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia. 2017;60:1691–703.CrossRef
31.
Degaard A, Lynggaard H, Rastam A, et al. No evidence of inscreased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52:2507–12.CrossRef
32.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–88.CrossRef
33.
Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, Nathan DM, Cleary PA, Backlung JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.CrossRef
34.
Diabetes Control and Complications trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general populations. Diabetes Care. 2016;39:1378–83.
35.
Kryszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-h C‑peptide and insulin secretion rate in nomal man. Diabetologia. 1987;30:16–21.CrossRef
36.
Gruden G, Giunti S, Baritta F, et al. QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care. 2012;35:125–7.CrossRef
37.
Pozzili P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. Diabetes Care. 2011;34(Suppl 2):S166–S70.CrossRef
38.
Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, Holl RW, DPD Initiative, German Competence Network Diabetes mellitus. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48–56.CrossRef
39.
Nwosi BU, Maranda L, Cullen K, Greenman L, Flechman L, McShea N, Barton BA, Lee MM. A randomized double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. PLoS One. 2015;10:e137525.CrossRef
40.
Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med. 2009;67:376–87.PubMed
41.
Heukamp I, Then C, Lechner A, Seissler J. Update Typ-1-Diabetes. Internist. 2013;54:201–16.CrossRef
42.
Schott M, Seissler J. Autoimmune polyendocrine syndromes. In: Renz H, Hrsg. Autoimmune diagnostics. Berlin: De Gruyter; 2012. S. S177–S89.
43.
Shun CB, Donaghue KC, Phelan H, Twigg SM, Craig ME. Thyroid autoimmunity in type 1 diabetes: systematic review and meta-analysis. Diabet Med. 2014;31:126–35.CrossRef
44.
Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004;350:2068–79.CrossRef
45.
Barker JM, Yu L, et al. Autoantibody “subspecificity” in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005;28:850–5.CrossRef
46.
Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet. 1994;8:83–7.CrossRef
47.
Triolo TM, Armstrong TK, McFann K, Yu L, Rewers MJ, Klingensmith GJ, Eisenbarth GS, Barker JM. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care. 2011;34:1211–3.CrossRef
48.
Umipierrez GE, Latif KA, Murphy MB, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care. 2003;26:1181–5.CrossRef
49.
Kordonouri O, Maguire AM, Knip M, Schober E, Lorini R, Holl RW, Donaghue KC, Other complications and associated conditions. ISPAD clinical practice consensus guidelines 2006–2007. Pediatr Diabetes. 2007;8:171–6.CrossRef
50.
Lampasona V, Bonfanti R, Bazzigaluppi E, et al. Antibodies to tissue transglutaminase C in type 1 diabetes. Diabetologia. 1999;42:1195–8.CrossRef
51.
Hogg-Kollars S, Al Dulaimi D, Tait K, Rostami K. Type 1 diabetes mellitus and gluten induced disorders. Gastroenterol Hepatol Bed Bench. 2014;7:189–97.PubMedPubMedCentral
52.
DeBlock C, de Leeuw I, Bogers J, et al. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care. 2003;26:82–8.CrossRef
53.
Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol. 1988;117:467–75.CrossRef
54.
Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051–76.CrossRef
55.
Valletta E, Fornaro M, Pecori S, Zanoni G. Selective immunoglobulin A deficiency and celiac disease: let’s give serology a chance. J Investig Allergol Clin Immunol. 2011;21:242–4.PubMed
56.
Schober E, Bittmann B, Granditsch G, Huber VVD, Hüppe A, Jäger A, Oberhuber G, Rami B, Reichel G. Screening by enti-endomysium antibody for celiac disease in diabetic children and adolescents in Austria. J Pediatr Gastroenterol Nutr. 2000;30:391–6.CrossRef
Metadaten
Titel
Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2019)
verfasst von
Monika Lechleitner
Susanne Kaser
Friedrich Hoppichler
Michael Roden
Raimund Weitgasser
Bernhard Ludvik
Peter Fasching
Yvonne Winhofer-Stöckl
Alexandra Kautzky-Willer
Guntram Schernthaner
Rudolf Prager
Thomas C. Wascher
Martin Clodi
Publikationsdatum
12.04.2019
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 1/2019
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-019-1493-6

Weitere Artikel der Sonderheft 1/2019

Zusammenfassung der Überarbeitungen 2019

  • vorwort

Insulinpumpentherapie bei Kindern, Jugendlichen und Erwachsenen (Update 2019)

  • leitlinien für die praxis

Ernährungsempfehlungen bei Diabetes mellitus (Update 2019)

  • Open Access
  • leitlinien für die praxis

Therapie der Hyperglykämie bei erwachsenen, kritisch kranken PatientInnen (Update 2019)

  • leitlinien für die praxis

Geriatrische Aspekte bei Diabetes mellitus (Update 2019)

  • leitlinien für die praxis

Positionspapier: Operation und Diabetes mellitus (Update 2019)

  • leitlinien für die praxis